Ligand Pharmaceuticals Inc
LGNDZ- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000886163
In the last 90 days, Ligand Pharmaceuticals Inc insiders filed 0 open-market purchases and 8 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $16 in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 31, 2026, 1:10 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 22, 2023 | Feb 17, 2022 |
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M | $277.1M |
| Research and development | $81.2M | $21.4M | $24.5M | $36.1M | $69.0M |
| Selling, general and administrative | $92.4M | $78.7M | $52.8M | $70.1M | $57.5M |
| Operating income | $41.0M | -$22.6M | $11.9M | $3.04M | $78.9M |
| Interest expense | – | – | $656.0K | $1.80M | $19.6M |
| Income tax | $34.5M | $6.55M | $9.84M | $41.2M | -$9.84M |
| Net income | $124.5M | -$4.03M | $52.2M | -$33.4M | $57.1M |
| EPS, basic | $6.44 | $-0.22 | $3.02 | $-1.98 | $3.44 |
| EPS, diluted | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 |
| Weighted shares, basic | 19.3M | 18.3M | 17.3M | 16.9M | 16.6M |
| Weighted shares, diluted | 20.3M | 18.3M | 17.8M | 16.9M | 17.2M |
| Margins and growth | |||||
| Operating margin | 15.3% | -13.5% | 9.1% | 1.5% | 28.5% |
| Net margin | 46.4% | -2.4% | 39.7% | -17.0% | 20.6% |
| Revenue growth, year over year | +60.4% | +27.3% | −33.1% | −29.2% | +48.7% |
| Net income growth, year over year | – | −107.7% | – | −158.4% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 22, 2023 | Feb 17, 2022 |
| Cash and equivalents | $174.9M | $72.3M | $23.0M | $45.0M | $19.5M |
| Short-term investments | $558.6M | $183.9M | $147.4M | $166.9M | $321.6M |
| Accounts receivable | $59.6M | $38.4M | $32.9M | $30.4M | $85.5M |
| Inventory | $9.13M | $14.1M | $24.0M | $13.3M | $27.3M |
| Total current assets | $832.3M | $331.6M | $237.4M | $263.6M | $464.8M |
| Property, plant and equipment | $3.57M | $15.1M | $15.6M | $12.5M | $20.5M |
| Goodwill | $101.5M | $105.3M | $103.4M | $105.7M | $181.2M |
| Intangible assets | $225.4M | $266.6M | $299.6M | $342.5M | $551.0M |
| Total assets | $1.56B | $941.8M | $787.2M | $762.7M | $1.30B |
| Accounts payable | $3.24M | $5.23M | $2.43M | $5.31M | $8.40M |
| Total current liabilities | $37.4M | $37.1M | $16.8M | $98.8M | $41.7M |
| Total liabilities | $543.4M | $111.3M | $86.3M | $165.2M | $476.4M |
| Shareholders' equity | $1.02B | $830.4M | $700.9M | $597.5M | $821.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 22, 2023 | Feb 17, 2022 |
| Operating cash flow | $49.4M | $97.0M | $49.6M | $137.8M | $78.8M |
| Capital expenditures | $452.0K | $1.82M | $3.52M | $17.9M | $8.76M |
| Free cash flow | $48.9M | $95.2M | $46.1M | $119.9M | $70.0M |
| Depreciation and amortization | $33.8M | $35.2M | $36.5M | $51.5M | $51.1M |
| Stock-based compensation | $46.8M | $41.1M | $25.7M | $60.3M | $38.8M |
| Share buybacks | $15.0M | – | – | $0 | $0 |
| Investing cash flow | -$377.3M | -$143.7M | -$11.7M | $163.6M | $30.5M |
| Financing cash flow | $428.2M | $97.1M | -$59.9M | -$276.0M | -$137.8M |
| Net change in cash | $102.6M | $49.4M | – | – | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 17.5% | 24.6% | 19.6% | 30.7% | 14.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 27, 2026 | 20.0M | +1.6% | SEC |
| Aug 4, 2026 | 19.9M | +1.7% | SEC |
| May 5, 2026 | 20.0M | +3.9% | SEC |
| Feb 24, 2026 | 19.9M | +3.6% | SEC |
| Nov 4, 2025 | 19.7M | +4.2% | SEC |
| Aug 5, 2025 | 19.6M | +7.3% | SEC |
| May 6, 2025 | 19.3M | +7.4% | SEC |
| Feb 25, 2025 | 19.3M | +8.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.